Predictive Analytics Monitoring for Clinical Deterioration in Cardiology
(PM-IMPACCT Trial)
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the treatment CoMET Display for predicting clinical deterioration in cardiology?
The CoMET Display uses real-time data to predict clinical deterioration, and studies show it can identify risk spikes that indicate a higher chance of needing intensive care. This predictive monitoring has been shown to improve early detection of patient decline, potentially allowing for timely interventions.12345
Is the CoMET Display safe for use in humans?
How does the CoMET Display treatment differ from other treatments for predicting clinical deterioration in cardiology?
The CoMET Display treatment is unique because it uses continuous predictive analytics monitoring, which relies on real-time data from ECG and other clinical assessments to predict clinical deterioration, unlike traditional methods that use static or intermittent data inputs. This approach allows for more personalized alert thresholds based on individual patient baselines, potentially improving early detection of deterioration.12589
What is the purpose of this trial?
Hypothesis: display of predictive analytics monitoring on acute care cardiology wards improves patient outcomes and is cost-effective to the health system.The investigators have developed and validated computational models for predicting key outcomes in adults, and a useful display has been developed, implemented and iteratively optimized. These models estimate risk of imminent patient deterioration using trends in vital signs, labs and cardiorespiratory dynamics derived from readily available continuous bedside monitoring. They are presented on LCD monitors using software called CoMET (Continuous Monitoring of Event Trajectories; AMP3D, Advanced Medical Predictive Devices, Diagnostics, and Displays, Charlottesville, VA)To test the impact on patient outcomes, the investigators propose a 22-month cluster-randomized control trial on the 4th floor of UVa Hospital, a medical-surgical floor for cardiology and cardiovascular surgery patients. Clinicians will receive standard CoMET device training. Three- to five-bed clusters will be randomized to intervention (predictive display plus standard monitoring) or control (standard monitoring alone) for two months at a time. In addition, risk scores for patients in the intervention clusters will be presented daily during rounds to members of the care team of physicians, residents, nurses, and other clinicians. Data on outcomes will be statistically compared between intervention and control clusters.
Research Team
Jamieson M Bourque, MD
Principal Investigator
University of Virginia Health System
Eligibility Criteria
This trial is for adult patients staying in a specific cardiology and cardiovascular surgery ward at UVa Hospital. They must be assigned to a bed that's part of the study's randomized clusters. There are no exclusion criteria, so all eligible patients in these beds can participate.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Training
Clinicians receive standard CoMET device training
Intervention
Cluster-randomized control trial with intervention and control groups, using predictive display and standard monitoring
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- CoMET Display
Find a Clinic Near You
Who Is Running the Clinical Trial?
Jamieson Bourque, MD
Lead Sponsor
Advanced Medical Predictive Devices, Diagnostics and Displays, Inc.
Collaborator